Abstract: Methods and apparatuses are provided for producing hydrocarbons. A method for producing hydrocarbons may include two or more reactors having a distributed aromatic rich feed and hydrogen system. Using this configuration, the aromatic rich feed and hydrogen streams are split equally to all reactors wherein each reactor contains a catalyst. The outlet from the last reactor may include a recycle that may be injected into the inlet of the first reactor.

Abstract: A process is presented for the removal of aromatics from an olefin stream. The process includes washing the olefin stream with a hydrocarbon stream to absorb aromatics generated in a dehydrogenation process. The olefin stream is compressed, then washed and cooled with a liquid hydrocarbon stream. The cooled and washed stream is passed to a separation drum to remove the liquid hydrocarbon stream containing the aromatics.

Abstract: A process is presented for the dehydrogenation of paraffins. The process utilizes the combustion of a fuel within the dehydrogenation reactor to provide the heat of reaction for dehydrogenation. The process controls the combustion through limiting the oxidant concentration. A paraffin feedstream is mixed with a fuel, and the fuel/paraffin feedstream is mixed with an oxidant stream at the inlet of each dehydrogenation reactor.

Abstract: Disclosed is a method for process for transalkylation of aromatic compounds comprising introducing a feed stream comprising aromatic hydrocarbon compounds to the transalkylation zone; introducing a water source to the transalkylation zone; contacting the feed stream with a zeolitic transalkylation catalyst; and producing an ethylbenzene product stream. This method increases ethylbenzene yield while improving the selectivity of the catalyst.

Abstract: A first method for refining dicyclopentadiene of the present invention is characterized in that the method separates and recovers dicyclopentadiene by distilling the crude dicyclopentadiene that contains dicyclopentadiene and is obtained by removing a C5 fraction and a BTX fraction from the reaction product obtained by dimerization reaction of the cracked gasoline by-produced in an ethylene plant that uses as feed stock a C2 fraction, a C3 fraction and a C4 fraction. A second method for refining dicyclopentadiene of the present invention is characterized in that the dicyclopentadiene-containing fraction refined by distillation is brought into contact with an inert gas or a hydrocarbon gas having 1 to 3 carbon atoms.

Abstract: The present subject matter relates to methods and apparatuses for the continuous preparation of a cumene feed for a cumene oxidation process. More specifically, the subject matter relates to a process for passing a cumene alpha-methylstyrene stream through a caustic wash column having an integrated water wash section for the removal of organic acids.

Abstract: The present subject matter relates to methods and apparatuses for the continuous preparation of a cumene feed for a cumene oxidation process. More specifically, the subject matter relates to a process for passing a cumene alpha-methylstyrene stream through a caustic wash column having an integrated water wash section for the removal of organic acids.

Abstract: A method of recovering an alcohol from an aqueous stream comprising: providing an aqueous stream comprising water and an alcohol; providing a solvent stream; combining the aqueous stream and the solvent stream; and recovering at least a portion of the alcohol by liquid-liquid extraction.

Abstract: A method for suppressing isomerization of an olefin metathesis product produced in a metathesis reaction includes adding an isomerization suppression agent to a mixture that includes the olefin metathesis product and residual metathesis catalyst from the metathesis reaction under conditions that are sufficient to passivate at least a portion of the residual metathesis catalyst. The isomerization suppression agent includes (i) a salt and/or an ester of a phosphorous oxo acid, and/or (ii) a derivative of the phosphorous oxo acid in which at least one P—H bond has been replaced by a P—C bond, and/or (iii) a salt and/or an ester of the derivative. Methods of refining natural oils are described.

Abstract: The present invention describes a process for preparing alpha-beta-unsaturated carboxylic acids by dehydration of hydroxycarboxylic or alkoxycarboxylic acids which are substituted in the alpha position, in particular 2-hydroxyisobutyric acid, while avoiding accumulation of by-products and additives.

Abstract: A method of producing a powder of fatty acid metal salt for forming ultrafine metal particles includes washing the fatty acid metal salt so that the amount of unreacted substance or by-product is 4.0 mol % or less when the fatty acid metal salt is formed; preparing a pressed cake by pressing the fatty acid metal salt; and drying the pressed cake so that the water content is 200 ppm or less. The powder has a property for deodorizing mercaptan smelling components and/or a property for inactivating microproteins.

Abstract: Processes for separating a di-carboxylic acid or salt thereof from a mixture containing the di-carboxylic acid or salt thereof and one or more other components are provided. Also separation media useful for these separation processes is provided. In particular, processes for preparing an aldaric acid are described, such as glucaric acid from glucose, which includes separating the aldaric acid from the reaction product. Also, various glucaric acid products are described.

Abstract: The present invention relates to the process for recovering acrylic acid, comprising the steps a) division of a heated mother acid stream in direction of an absorption column (201) and a dissociation column (205), b) feeding of a heated mother acid substream as runback to the dissociation column (205), c) feeding-in of at least one stripping gas stream to the dissociation column (205), d) feeding-in of a secondary component stream comprising oligomeric acrylic acid from the condensation column (201) to the dissociation column (205), e) dissociation of part of oligomeric acrylic acid in the dissociation column (205) to give monomeric acrylic acid, f) removal of secondary components comprised in the secondary component stream in the dissociation column (205), g) discharge of monomeric acrylic acid as gas mixture with introduced circulating stripping gas stream from the dissociation column (205) and h) feeding-in of the gas mixture to the condensation column (201).

Abstract: The invention relates to a process for preparing a C8-C24 alkyl(meth)acrylate by transesterification of methyl(meth)acrylate with a C8-C24 alkanol, said process comprising the steps of: (i) reacting methyl(meth)acrylate with the C8-C24 alkanol in the presence of a tin-comprising catalyst and a stabilizer in the presence of an entraining agent which forms an azeotrope with methanol, (ii) continuously distilling off the azeotrope of entraining agent and methanol wherein steps (i) and (ii) are carried out simultaneously until the C8-C24 alkanol has been substantially completely reacted, (iii) washing with an aqueous alkaline washing solution the C8-C24 alkyl (meth)acrylate-comprising product mixture obtained in steps (i) and (ii) to remove from the product mixture the tin-comprising catalyst and at least some of the stabilizer, (iv) distilling off unconverted methyl(meth)acrylate and entraining agent from the product mixture, (v) distilling off water from the product mixture wherein a product having a by-product

Abstract: The present invention relates to novel multifunctional acrylic monomers which are acrylic ether-ester products based on a mixture of multifunctional acrylic products derived from the reaction of acrylic acid in deficit with a multifunctional polyol, to a preparation process for the same, and to crosslinkable compositions based on these products.

Abstract: The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases.

Abstract: Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds display a preference for specific ubiquitin specific proteases (USPs).

Abstract: A method for the purification and preparation of melphalan that allows to obtain melphalan with purity higher than 99.5% is described.

Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A sulfonium salt of formula (0-1) is provided wherein W is alkylene or arylene, R01 is a monovalent hydrocarbon group, m is 0, 1 or 2, k is an integer: 0?k?5+4m, R101, R102 and R103 are a monovalent hydrocarbon group, or at least two of R101, R102 and R103 may bond together to form a ring with the sulfur atom, and L is a single bond, ester, sulfonic acid ester, carbonate or carbamate bond. A resist composition comprising the sulfonium salt as PAG exhibits a very high resolution when processed by EB and EUV lithography. A pattern with minimal LER is obtainable.

Abstract: Novel methods and systems for producing a substantially pure d-threo stereoisomer of methylphenidate or a salt thereof are provided. In particular, methods and systems for producing d-threo-methylphenidate hydrochloride in pure stereoisomeric form from d-threo-ritalinic acid hydrochloride using diazomethane are described. The described methods can be performed on a large scale, and thus provide d-threo methylphenidate or a salt thereof, and particularly the hydrochloride salt of d-threo-methylphenidate, in stereoisomerically pure form and in large quantities from a single batch reaction. Also described are novel compositions of d-threo methylphenidate hydrochloride.

Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.

Abstract: The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.

Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.

Abstract: The present invention provides a one step carbonylation of a compound of formula II in the presence of water to afford a compound of formula (I), useful in processes to manufacture BACE inhibitors.

Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.

Abstract: The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.

Abstract: A pyridazine compound represented by formula [1]: which is useful as an active ingredient of a plant disease control agent can be produced, by steps of obtaining a compound represented by formula [3]: by reacting a compound represented by formula [4]: with a compound represented by formula [5]: obtaining a compound represented by formula [2]: by deprotecting the compound [3]; and reacting the compound [2] with a chlorinating agent.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Abstract: Disclosed in the present invention is a preparation method of azoxystrobin having a structure as shown by formula (1), the method comprising: a) performing an etherification reaction by reacting the compound having a structure shown by formula (2) with 2-cyanophenol and/or a salt thereof under the catalysis of an azabicyclo tertiary amine compound and/or a salt thereof as the catalyst in a butyl acetate medium to obtain a butyl acetate solution containing azoxystrobin; and b) cooling the butyl acetate solution containing azoxystrobin to precipitate Azoxystrobin having a structure as shown by formula (1) from the butyl acetate solution. Using the method provided by the present invention to prepare azoxystrobin can significantly improve the yield of azoxystrobin, and can obtain azoxystrobin products having high purity.

Abstract: Disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: X1-L-X2 wherein L is a linking moiety comprising an enone; and X1 and X2 are each independently an optionally-substituted N-heterocycle. Also disclosed are method for treating pulmonary conditions and other organ or system conditions with the compounds.

Abstract: Impure aryltriazoles such as benzotriazole and tolyltriazole that are contaminated with dark colored impurities can be purified by conversion to an aryltriazole acid salt by treatment with aqueous acid. The aryltriazole acid salt is water soluble whereas the dark colored impurities are not. The aryltriazole acid salt solution is separated from the dark colored impurities and the aryltriazole acid salt is isolated by precipitation. The free aryltriazole may be recovered by neutralization with base.

Abstract: A Pentamethylene diisocyanate is obtained by phosgenating pentamethylenediamine or its salt obtained by a biochemical method, and contains 5 to 400 ppm of a compound represented by the general formula (1) below and a compound represented by the general formula (2) below in total:

Abstract: The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.

Abstract: A method to produce levulinic acid (LA) and gamma-valerolactone (GVL) from biomass-derived cellulose or lignocellulose by selective extraction of LA using GVL and optionally converting the LA so isolated into GVL, with no purifications steps required to yield the GVL.

Abstract: Compound containing a pentalene unit having general formula (I) wherein R1 and R2, equal to or different from each other, are selected from: linear or branched C1-C20, preferably C2-C12, alkyl groups, saturated or unsaturated, optionally containing heteroatoms, cycloalkyl groups optionally substituted, linear or branched C1-C20, preferably C2-C12, alkoxyl groups, saturated or unsaturated, optionally substituted; or the groups R1 and R2 can be optionally bound to each other so as to form, together with the carbon atoms to which they are bound, a cycle or a polycyclic system containing from 3 to 14 carbon atoms, preferably from 4 to 6 carbon atoms, saturated, unsaturated, or aromatic, optionally containing one or more heteroatoms such as, for example, oxygen, sulfur, nitrogen, silicon, phosphorous, selenium; R3 is selected from aryl groups optionally substituted, heteroaryl groups optionally substituted; n is 0 or 1; with the proviso that: when n is 0, X represents a covalent bond and Y represents a sulfur atom

Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.

Abstract: Disclosed are crystalline forms of a compound of formula (I), methods of their preparation, and related pharmaceutical preparations thereof.

Abstract: The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

Abstract: Compounds are provided having an excellent hypoglycemic effect and ? cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

Abstract: The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: The invention relates to the compounds of formula I and formula Ia or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of formula I or formula Ia; and methods for treating or preventing epilepsy, seizures and convulsions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures and convulsions.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Abstract: Compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and/or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.

Abstract: The invention relates to antibacterial compounds of formula I wherein R, M and A are as defined in the description, to pharmaceutical compositions containing them and uses of these compounds in the manufacture of medicaments for the treatment of bacterial infections.

Abstract: Use of a tetramic acid compound according to formula (I) or (I?) with a second nematicide as a treatment for crop plants to combat and control nematodes in the soil of said crop plants.